AZArjan D. van Zuilen

Arjan D. van Zuilen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arjan D. van Zuilen has a total of 219 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Continuous Diagnostic Indices from BanffNET Automated Lesion Scores for Kidney Transplant Pathology: Development and Evaluation of a Diagnostic Prediction Model

    by Arthur Vranken, Giorgio Buzzanca, Thibaut Vaulet, Karolien Wellekens, Priyanka Koshy, Danny van der Helm, Soufian Meziyerh, Jan-Hendrik Venhuizen, Saskia Haitjema, Arjan D. van Zuilen, et al.

    Background: Histopathological diagnoses in kidney transplant biopsies, as described by the Banff classification, suffer from substantial inter-observer variability and misinterpretation, making them prone to diagnostic errors. Continuous indices based on BanffNET automated lesion scores are proposed to quantify the continuous phenotypic spectrum of kidney transplant biopsies, complementary to pathologist assessment of biopsies. Methods: The BanffNET model was used to obtain continuous lesion scoring for a training cohort of 2544 biopsies, a large validation cohort of 3863 biopsies, and a multi-reader cohort of 36 biopsies scored by 67 pathologists. A penalized regression approach was used to condense 17 automated lesion scores into four indices, representing the most important dimensions of graft injury: a TCMR/TI Index, an AMR/MVI Index, an Activity Index and a Chronicity Index. The BanffNET Indices were evaluated against Banff diagnoses and histological indices in the training cohort and validation cohort. Since pathologist-assigned Banff lesions and diagnoses suffer from inter-observer variability, associations were also assessed with diagnoses in a multi-reader study, with time to kidney graft failure in the training and validation cohort and with biopsy-based molecular signatures in the validation cohort. Results: The BanffNET TCMR/TI Index, AMR/MVI Index and Activity Index showed excellent discrimination of Banff TCMR, Banff MVI and Banff Any Diagnosis respectively, with validation AUCs ranging from 0.80 to 0.92. In addition, the BanffNET Indices explained large amounts of variability in multi-observer reference standards, time to graft failure and molecular biopsy-based diagnostics. In the large majority of cases, variability explained by BanffNET Indices matched or exceeded the variability explained by pathologist-assigned diagnoses and histological indices. Conclusions: BanffNET Indices are reproducible descriptors of whole slide images that could complement and augment kidney transplant biopsy evaluation by pathologists. Associations of BanffNET Indices with multi-observer diagnoses and related outcomes suggest that they capture additional information on tissue injury type and severity on top of pathologist-assigned Banff diagnoses and histological indices.

  • Open Access

    Unveiling Donor-Derived BKPyV DNAemia Through Analysis of Contralateral Kidney Transplant Recipients

    by Wouter T. Moest, A. Lianne Messchendorp, Helma Dolmans, Cynthia Konijn-Janssen, Stan van Den Eijnden, Milou van Bruchem, Ineke Tieken, Maarten H. L. Christiaans, Arjan D. van Zuilen, Marcia M. L. Kho, et al.

    Background: BK polyomavirus (BKPyV) infection is of notable concern in kidney transplant recipients, as it can cause BKPyV-associated nephropathy (BKPyVAN). Currently, there is no effective treatment for BKPyV infection, underscoring the need for preventive strategies. There is emerging evidence that donor-derived BKPyV plays a role in the development of BKPyV DNAemia. To further explore this hypothesis, we conducted a retrospective, multi-center cohort study to evaluate the risk of developing BKPyV DNAemia in kidney recipient pairs sharing the same donor. Methods: At the Leiden University Medical Center (LUMC), deceased donor kidney transplant recipients (2011–2021) were identified and classified according to the occurrence of BKPyV DNAemia within the first year post-transplantation. For each recipient, the contralateral kidney recipient from the same donor was identified through national transplant registries. Cox regression was used to assess whether BKPyV DNAemia in the LUMC recipient was associated with an increased risk of BKPyV DNAemia in the contralateral recipient. Results: Among 117 recipient pairs, BKPyV DNAemia was more frequent when the contralateral recipient was affected (28.8% [15/52]), compared with pairs in which the contralateral recipient remained unaffected (10.8% [7/65], p = 0.013). Multivariable Cox regression analysis confirmed this increased risk (HR 4.9, 95% CI: 1.8–13.6; p = 0.002). Conclusions: This study shows a significantly increased risk of BKPyV DNAemia in recipients of deceased donor kidneys when the contralateral kidney recipient develops BKPyV DNAemia. These findings highlight the influence of donor-derived factors in BKPyV transmission in kidney transplantation.

  • Open Access

    Comparable outcomes for old, older, and very old deceased donors in old kidney transplant recipients

    by Silke E. de Boer, Erzsi Tegzess, Daan Kremer, Frederike J. Bemelman, Maarten H.L. Christiaans, Luuk B. Hilbrands, Aiko P.J. de Vries, Dorottya K. de Vries, Jacqueline van de Wetering, Hendrikus J.A.N. Kimenai, et al.


  • Open Access

    Organ Donor Potential After Extracorporeal Cardiopulmonary Resuscitation for Out‐of‐Hospital Cardiac Arrest: A Post‐Hoc Analysis of a Randomized Controlled Trial

    by Hanne C. R. Verberght, Thijs S. R. Delnoij, Martje M. Suverein, Jody Lunsing, Renicus C. Hermanides, Luuk Otterspoor, Carlos V. Elzo Kraemer, Alexander P. J. Vlaar, Joris J. van der Heijden, Erik Scholten, et al.

    Background: Extracorporeal cardiopulmonary resuscitation (ECPR) is a potentially life‐saving intervention in refractory out‐of‐hospital cardiac arrest (OHCA). ECPR enables, in most of the treated cases, ICU admission to patients who otherwise would have died at the emergency department (ED). Still, many of them die, frequently after withdrawal of life‐sustaining therapies due to irreversible critical conditions and related complications. The additional time provided by ECPR, however, might allow for the assessment of organ donor suitability. The aim of this study was to evaluate the impact of ECPR on the number of potential organ donors after refractory OHCA. Methods: We performed a post‐hoc analysis of the multicenter INCEPTION trial, which randomized 134 OHCA patients between conventional CPR (CCPR) and ECPR. Detailed patient reports were presented to transplant physicians to determine the acceptability of the liver and kidneys for organ donation. In addition to the intention to treat analysis, we performed an “as‐treated” analysis, limited to patients arriving without return of spontaneous circulation (ROSC) at the ED. Results: Out of 70 patients randomized to ECPR and 64 to CCPR, potential organ donors were identified in 14 (20%) and 4 (6%) patients, respectively ( χ 2 test, p = 0.038). In the as‐treated analysis, 15 out of 55 (27%) treated with ECPR were potential donors, compared to 0 out of 59 treated with CCPR ( p < 0.001). This included five (9%) potential kidney donors and 15 (27%) potential liver donors. Conclusion: Although ECPR is currently used with life‐saving intentions, it may simultaneously increase the number of potential organ donors following cardiac arrest in selected patients. Trial Registration: ClinicalTrials.gov identifier: NCT03101787

  • Open Access

    Immunosuppression in Older Kidney Transplant Recipients

    by Jan-Stephan F. Sanders, Silke E. de Boer, Jip Jonker, Frederike J. Bemelman, Michiel G.H. Betjes, Aiko P.J. de Vries, Luuk Hilbrands, Marc Hilhorst, Dirk R.J. Kuypers, Priya Vart, et al.

    Key Points: Low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in older kidney transplant recipients. Low-dose tacrolimus, everolimus, and prednisolone did not result in better kidney function or fewer infections in older kidney transplant recipients. Background: We hypothesized that older kidney transplant recipients receiving low-dose tacrolimus, everolimus, and prednisolone (TEP) have better outcomes than patients receiving standard-dose tacrolimus, mycophenolate mofetil, and prednisolone (TMP). Methods: The OPTIMIZE study was a randomized clinical trial in kidney transplant recipients age ≥65 years. Patients receiving a kidney from a deceased donor older than 65 years (stratum A) or a kidney from a deceased donor younger than 65 years or a living donor (stratum B) were included. Patients were randomized to TEP or TMP groups. Tacrolimus target trough levels in the TEP group were 5–7 ng/ml until 3 months, 2–4 ng/ml from 3 to 6 months, and 1.5–4 ng/ml from 6 months onwards. Tacrolimus target trough levels in the TMP group were 8–12, 6–10, and 5–8 ng/ml. Everolimus target trough levels were 3–6 µ g/L. The primary end point of successful transplantation was defined as being alive with a functioning graft with an eGFR above a predefined threshold at 2 years after transplantation. Predefined eGFR thresholds were 30 (stratum A) or 45 ml/min per 1.73 m 2 (stratum B). Results: A total of 379 patients were randomized, of whom 198 were in stratum A (TEP 97, TMP 101) and 181 in stratum B (TEP 90, TMP 91). The median trough levels for everolimus and tacrolimus were within the target range throughout the study. There was no statistically significant difference in successful transplantation at 2 years between the groups (TEP 94 [50%], TMP 110 [57%]; difference 7% [95% confidence interval, −17 to 3] P = 0.91). Regarding the predefined secondary outcomes, patient survival (TEP 167 [89%], TMP 171 [89%]; P = 0.95) and graft survival (TEP 155 [83%], TMP 162 [84%]; P = 0.65) did not differ significantly. Within strata A and B, there were no significant differences in the end points. Conclusions: Immunosuppression with low-dose tacrolimus, everolimus, and prednisolone did not result in a higher rate of successful transplantation in de novo older kidney transplant recipients compared with immunosuppression with standard-dose TMP. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT03797196.


  • Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression

    by Tom Greene, Willem Collier, Benjamin Haaland, Chong Zhang, Sunil V. Badve, Fernando Caravaca-Fontán, Lucia Del Vecchio, Jürgen Floege, Thierry Hannedouche, Enyu Imai, et al.

    Key Points: Acute effects impact the clinical endpoint independently of treatment effects on the chronic slope. Our findings support the 3-year total slope as the primary slope-based outcome in randomized trials. Background: Slope of the GFR is considered a validated surrogate endpoint for CKD trials. However, differing short-term and long-term treatment effects on GFR slope can create ambiguities concerning the appropriate period for evaluating slope, in part because current methods cannot separate the distinct contributions of the acute (before 3 months) and chronic (after 3 months) slopes for treatment effects on clinical endpoints (CEs). Methods: We estimated treatment effects on the acute and chronic GFR slopes and on the established CE of kidney failure or serum creatinine doubling for 66 randomized treatment comparisons from previous CKD clinical trials. We used a novel Bayesian meta-regression framework to relate treatment effects on the established CE to both the acute and chronic slopes in a single multivariable model to determine the independent contributions of the acute and chronic slopes. Results: Treatment effects on both the acute and chronic slopes independently predicted the treatment effect on the established CE with a high median R2 (95% credible interval) of 0.95 (0.79 to 1.00). For a fixed treatment effect on the chronic slope, each 1 ml/min per 1.73 m2 greater acute GFR decline for the treatment versus control increased the hazard ratio for the established CE by 11.4% (7.9%–15.0%), against the treatment. The optimal weights for the acute and chronic slopes were consistent with the 3-year total slope defined as the average slope extending from baseline to 3 years. Conclusions: Treatment effects on both the acute and chronic GFR slopes are independent determinants of the effects on the established CE, with variation in acute effects accounting for much of the observed variation in treatment effects on the CE across previous trials. Our results establish that acute effects affect the CE independently of treatment effects on the chronic slope and support the 3-year total slope as the primary slope-based outcome in randomized trials.


  • Open Access

    Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial

    by A Lianne Messchendorp, Luca M Zaeck, Pim Bouwmans, Dennis A J van Den Broek, Sophie C Frölke, Daryl Geers, Céline Imhof, S Reshwan K Malahe, Katharina S Schmitz, Julian Reinders, et al.

    Background: Vaccine immunogenicity is reduced in kidney transplant recipients (KTRs), especially in those using mycophenolate mofetil (MMF). Whether replacement of MMF by everolimus improves vaccine immunogenicity is unknown. Methods: KTRs were randomized 1:1 to continue MMF or switch to everolimus. Participants received one coronavirus disease 2019 (COVID-19) booster vaccination and two herpes zoster (HZ) vaccinations at 6, 10 and 14 weeks postrandomization. Primary outcome was the neutralizing antibody response 28 days after COVID-19 vaccination. Secondary outcomes included antibody and T-cell responses 28 days after COVID-19 and HZ vaccination, and safety. Results: In 110 KTRs, COVID-19 vaccination resulted in comparable Omicron XBB.1.5 neutralizing antibody titers in the everolimus versus MMF group (308 [74.4–1314] vs 327 [115–897]; P = .83), whereas severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Spike-specific T-cell responses were slightly lower with everolimus (118 [32.1–243] vs 228 [113–381] spot-forming cells [SFCs]/106 peripheral blood mononuclear cells [PBMCs]; P = .02). HZ vaccination led to higher varicella zoster virus (VZV) glycoprotein E (gE)–specific immunoglobulin G titers with everolimus (2192 [888–4523] vs 1101 [440–2078] 50% endpoint titer; P = .004), while VZV gE-specific T-cell responses were similar (85.0 [27.5–155] vs 115 [50.0–258] SFCs/106 PBMCs; P = .24). Besides known side effects, everolimus led to more bacterial infections (27.3% vs 11.1%; P = .03). Conclusions: Six weeks’ replacement of MMF by everolimus in KTRs does not improve COVID-19 booster vaccine immunogenicity, whereas 10 weeks’ replacement enhances humoral HZ vaccine immunogenicity. While replacing MMF by everolimus may improve vaccine responses, its timing and potential risks require careful consideration.


  • Open Access

    Favorable Living Donor Kidney Transplantation Outcomes within a National Kidney Exchange Program

    by Stijn C. van de Laar, Annelies E. de Weerd, Frederike J. Bemelman, Mirza M. Idu, Aiko P.J. de Vries, Ian P.J. Alwayn, Stefan P. Berger, Robert A. Pol, Arjan D. van Zuilen, Raechel J. Toorop, et al.

    Key Points: KEP recipients have comparable long-term graft survival to direct living donor kidney transplantation recipients, which underscores the need to prioritize KEP over other's therapies. Our outcomes can be achieved regardless of whether the donor travels or the graft is transported, offering flexibility in program implementation. Background: KEPs (kidney exchange programs) facilitate living donor kidney transplantations (LDKTs) for patients with incompatible donors, who are typically at higher risk than non-KEP patients because of higher sensitization and longer dialysis vintage. We conducted a comparative analysis of graft outcomes and risk factors for both KEP and non-KEP living donor kidney transplants. Methods: All LDKTs performed in The Netherlands between 2004 and 2021 were included. The primary outcome measures were 1-, 5-, and 10-year death-censored graft survival. The secondary outcome measures were delayed graft function, graft function, rejection rates, and patient survival. We used a propensity score–matching model to account for differences at baseline. Results: Of 7536 LDKTs, 694 (9%) were transplanted through the KEP. Ten-year graft survival was similar for KEP (0.916; 95% confidence interval, 0.894 to 0.939) and non-KEP (0.919; 0.912 to 0.926, P = 0.82). We found significant differences in 5-year rejection (12% versus 7%) and 5-year patient survival (KEP: 84%, non-KEP: 90%), which was nonsignificant after propensity score matching. Significant risk factors of lower graft survival included high donor age, retransplantations, extended dialysis vintage, higher panel reactive antibodies, and nephrotic syndrome as the cause of ESKD. Conclusions: Transplantation through KEP offers a viable alternative for patients lacking compatible donors, avoiding specific and invasive pre- and post-transplant treatments. KEP's similar survival rate to non-KEPs suggests prioritizing KEP LDKTs over deceased donor kidney transplantation, desensitization, and dialysis. However, clinicians should consider the identified risk factors when planning and managing pre- and post-transplant care to enhance patient outcomes. Thus, we advocate for the broad adoption of KEP and establishment in regions lacking such programs, alongside initiation and expansion of international collaborations.


  • Open Access

    The differential impact of early graft dysfunction in kidney donation after brain death and after circulatory death: Insights from the Dutch National Transplant Registry

    by Thei S. Steenvoorden, Lara Evers, Liffert Vogt, Janneke A.J. Rood, Jesper Kers, Marije C. Baas, Maarten H.L. Christiaans, Jan H.N. Lindeman, Jan-Stephan F. Sanders, Aiko P.J. de Vries, et al.


  • Open Access

    Direct mass spectrometry-based detection and antibody sequencing of Monoclonal Gammopathy of Undetermined Significance from patient serum – a case study

    by Weiwei Peng, Maurits A. Den Boer, Sem Tamara, Nadia J. Mokiem, Sjors P. A. van der Lans, Douwe Schulte, Pieter-Jan Haas, Monique C. Minnema, Suzan H.M. Rooijakkers, Arjan D. van Zuilen, et al.

    Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder, characterized by the presence of a predominant monoclonal antibody ( i . e ., M-protein) in serum, without clinical symptoms. Here we present a case study in which we detect MGUS by liquid-chromatography coupled with mass spectrometry (LC-MS) profiling of IgG1 in human serum. We detected a Fab-glycosylated M-protein and determined the full heavy and light chain sequences by bottom-up proteomics techniques using multiple proteases, further validated by top-down LC-MS. Moreover, the composition and location of the Fab-glycan could be determined in CDR1 of the heavy chain. The outlined approach adds to an expanding mass spectrometry-based toolkit to characterize monoclonal gammopathies such as MGUS and multiple myeloma, with fine molecular detail. The ability to detect monoclonal gammopathies and determine M-protein sequences straight from blood samples by mass spectrometry provides new opportunities to understand the molecular mechanisms of such diseases.